AKBA - アケビア・セラピュ―ティクス (Akebia Therapeutics Inc.) アケビア・セラピュ―ティクス

 AKBAのチャート


 AKBAの企業情報

symbol AKBA
会社名 Akebia Therapeutics Inc (アケビア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アケビ・セェラァピュゥーティィクス(Akebia Therapeutics Inc.)はバイオ医薬品企業である。同社は低酸素誘導性因子(HIF)の生物学に基づいた治療薬の開発と商品化に従事する。同社の主力な候補製品のバダデュスタットは、慢性腎疾患(CKD)における貧血の治療に適応される。同社は経口療法におけるバダダスタットの開発を行う。バダスタットは、CKDの貧血の治療のためのフェーズⅢ開発におけるHIF-プロリルヒドロキシラーゼ(HIF-PH)阻害剤である。また、同社は疾患を標的とするHIFベースの候補製品のポートフォリオの開発に従事する。同社のポートフォリオは、社内で開発された候補製品のAKB-6899、ライセンス取得済みの候補製品のAKB-5169を含む。AKB-5169は、炎症性腸疾患(IBD)のための経口治療として開発中の前臨床化合物である。   アケビア・セラピュ―ティクスは米国のバイオ医薬品会社。低酸素誘導因子、HIF、生物学と腎臓病の患者用製品の商品化に基づく独自の治療法の開発に焦点を当てる。 「HIF」は体内で赤血球の生産と貧血を治療する。「AKB-6548」は一日一回の経口療法、「AKB-6548」は安定的にヘモグロビンレベルを上昇させる。本社はマサチュ―セッツ州ケンブリッジ。   Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
本社所在地 245 First Street Suite 1100 Cambridge MA 02142 USA
代表者氏名 Muneer A. Satter ムネア・サッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-871-2098
設立年月日 39114
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 114人
url www.akebia.com
nasdaq_url https://www.nasdaq.com/symbol/akba
adr_tso
EBITDA EBITDA(百万ドル) -72.19200
終値(lastsale) 8.59
時価総額(marketcap) 490029976.17
時価総額 時価総額(百万ドル) 484.88320
売上高 売上高(百万ドル) 223.32200
企業価値(EV) 企業価値(EV)(百万ドル) 82.76020
当期純利益 当期純利益(百万ドル) -68.34100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akebia Therapeutics Inc revenues increased 92% to $94.7M. Net loss decreased 13% to $57.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $1.4M (expense) Interest income increase from $1M to $2.6M (income) Other Non Rec.

 AKBAのテクニカル分析


 AKBAのニュース

   Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference  2020/05/08 12:00:00 PR Newswire
CAMBRIDGE, Mass., May 8, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate…
   Akebia Spikes 38% On Positive Readout for Pivotal Trial; And Further Upside Lies Ahead  2020/05/06 05:49:49 Smarter Analyst
Biopharma Akebia Therapeutics (AKBA) skyrocketed 38% in Tuesday’s trading after reporting positive topline data from the global Phase 3 clinical trials of vadadustat. … The post Akebia Spikes 38% On Positive Readout for Pivotal Trial; And Further Upside Lies Ahead appeared first on Smarter Analyst .
   Akebia Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation  2020/05/05 12:41:58 Seeking Alpha
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with their 2020 Q1 earnings call.
   Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results  2020/05/05 11:30:00 PR Newswire
CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, its investigational oral hypoxia-inducible…
   Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients  2020/05/05 11:01:00 Business Wire
ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anaemia due to Chronic Kidney Disease (CKD) in adult dialysis-dependent pa
   A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:  2020/03/16 01:28:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--At Akebia Therapeutics, the health of our patients and employees is our first priority. As a member of the kidney care community and the much broader biotechnology industry, we are taking proactive precautions to help mitigate the spread of COVID-19 and protect the safety and health of those around us, while adhering to our commitment to ensure that our patients continue to gain access to the therapies that they need. We are following guidance from the CDC to
   Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot  2020/03/10 12:11:49 news.alphastreet.com
— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share. — Revenue rose 16%…
   Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights  2020/03/10 11:49:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced financial results for the fourth quarter and full-year ended December 31, 2019. The Company will host a conference call today, Tuesday, March 10, 2020, at 9:00 a.m. Eastern Time to discuss its fourth quarter and full-year 2019 financial results and recent business highlight
   Akebia Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Discuss Recent Business Highlights  2020/02/24 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease, today announced plans to release its fourth quarter and full-year 2019 financial results, on Tuesday, March 10, 2020 before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Tuesday, March 10th, to discuss its fourth quarter and full-year 2019 f
   The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion  2020/02/21 12:46:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
   A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:  2020/03/16 01:28:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--At Akebia Therapeutics, the health of our patients and employees is our first priority. As a member of the kidney care community and the much broader biotechnology industry, we are taking proactive precautions to help mitigate the spread of COVID-19 and protect the safety and health of those around us, while adhering to our commitment to ensure that our patients continue to gain access to the therapies that they need. We are following guidance from the CDC to
   Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot  2020/03/10 12:11:49 news.alphastreet.com
— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share. — Revenue rose 16%…
   Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights  2020/03/10 11:49:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced financial results for the fourth quarter and full-year ended December 31, 2019. The Company will host a conference call today, Tuesday, March 10, 2020, at 9:00 a.m. Eastern Time to discuss its fourth quarter and full-year 2019 financial results and recent business highlight
   Akebia Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Discuss Recent Business Highlights  2020/02/24 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease, today announced plans to release its fourth quarter and full-year 2019 financial results, on Tuesday, March 10, 2020 before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Tuesday, March 10th, to discuss its fourth quarter and full-year 2019 f
   The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion  2020/02/21 12:46:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アケビア・セラピュ―ティクス AKBA Akebia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)